Cardiol Therapeutics (CRDL) Notes Payables (2021 - 2026)

Cardiol Therapeutics' (CRDL) quarterly Notes Payables came in at $2.7 million in Q1 2026, up 74.44% on a QoQ basis from $1.5 million in Q4 2025.

Cardiol Therapeutics (CRDL) Notes Payables (2021 - 2026) Analysis & Trends

Cardiol Therapeutics (CRDL) has 6 years of Notes Payables data on file, last reported at $2.7 million in Q1 2026.

Quarterly Notes Payables changed N/A year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (changed N/A YoY) and the FY2025 annual result came in at $1.5 million, changed N/A from the prior year.
Notes Payables improved to $2.7 million in Q1 2026, from $1.5 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $3.6 million in Q1 2022 to a low of $2673.4 in Q3 2024.
A 5-year average of $1.3 million and a median of $991230.6 in 2024 frame the typical range for Notes Payables.
The widest YoY moves for Notes Payables: up 493.8% in 2024, down 99.56% in 2024.
Tracing CRDL's Notes Payables over 5 years: stood at $309342.3 in 2022, then tumbled by 43.44% to $174948.7 in 2023, then plunged by 98.47% to $2673.4 in 2024, then soared by 57243.04% to $1.5 million in 2025, then soared by 74.44% to $2.7 million in 2026.
The last three Notes Payables figures came in at $2.7 million (Q1 2026), $1.5 million (Q4 2025), and $2673.4 (Q3 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-
2	Teva Pharmaceutical Industries	43.07 Bn	39.42 Bn	2.15 Bn
3	Zoetis	31.53 Bn	29.85 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.60 Bn	22.80 Bn	5.10 Bn
5	United Therapeutics	22.13 Bn	19.47 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.53 Bn	15.14 Bn	935.80 Mn
8	Elanco Animal Health	11.69 Bn	11.16 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.13 Bn	9.97 Bn	-
10	Cardiol Therapeutics	211.60 Mn	192.74 Mn	-

Download Data